Dr. Dipti Patel's Credentials

Accepting New Patients

Yes, this doctor is accepting new patients

Biography

Dr. Patel-Donnelly is triple board-certified in medical oncology, hematology, and internal medicine. She completed her fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her Doctorate of Medicine and completed her Internal Medicine Internship and Residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York. Dr. Patel-Donnelly has taken an active role at Virginia Cancer Specialists and in the local and medical communities. Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Medical Society of Virginia. Focusing on a special interest in hematologic malignancies, brain tumors, and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and currently serves as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and holds a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University. Dr. Patel-Donnelly has also received multiple awards and honors which include the Harvard Partners in Excellence Award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship, and Distinguished Honors and Independent Research in Biochemistry. Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian magazine. Additionally, she has been listed as a Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor. Dr. Patel-Donnelly is a published author and has spoken both at local educational events and in news interviews. Dr. Patel-Donnelly lives in Northern Virginia with her husband and two children. She is married to Dr. Donnelly at Georgetown University Medical Center whose expertise is in Internal Medicine and Pediatrics. She enjoys spending time with her family, cooking, running, traveling, and reading.

Languages

• Gujarati
• Hindi
• English

Education

• Mount Sinai School Of Medicine Of City University Of New York (Grad. 1996)
• Binghamton University (Grad. 1992)

Other Specialties

• Oncologist / Hematologist

Areas of Expertise

• Lymphoma
• Multiple myeloma
• Brain tumor
• Oncology
• Leukemia

Awards & Recognitions

• Castle Connolly Top Doctors 2020
• Washington Magazine Top Doctors 2020
• Castle Connolly Top Doctors 2013
• Castle Connolly Top Doctors 2012
• Washingtonian Top Doctor 2016
• Castle Connolly Top Doctors 2016
• Northern Virginia Magazine Top Doctor 2013
• Northern Virginia Magazine Top Doctor 2019
• 2020 Northern Virginia Magazine Top Doctors
• Castle Connolly Top Doctors 2018
• Northern Virginia Magazine Top Doctors 2018
• Washingtonian Magazine Top Doctors 2017
• Castle Connolly Top Doctors 2015
• Castle Connolly Top Doctors 2017
• Castle Connolly Top Doctors 2014
• Washingtonian Top Doctor 2014
• 2018 Washingtonian Magazine Top Doctor Nomination
• Castle Connolly Top Doctors 2019

Publications & Research

• Entospletinib Monotherapy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Previously Treated With B-cell Receptor Inhibitors: Results of a Phase 2 Study
• An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
• The dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy
• Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma
• WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY.
• Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
• Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
• Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline
• An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
• Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
• Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
• Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
• Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
• Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
• Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study